Urology Times staff

"[Low-grade prostate cancer] is a really interesting field right now," says Kevin Shee, MD, PhD.

“The takeaway from that talk was that it's critically important to review drug plan options, particularly if the patient's on a high-cost drug,” says Kelly L. Stratton, MD, FACS.

“The idea of generally screening everyone right now is not only costly, but it's not recognizing the fact that this comes with a lot of limitations,” says Mark A. Moyad, MD, MPH.

Ashley E. Ross, MD, PhD, provides an overview of his institution’s new protocol for this subset of patients.

“[The 2022 Huggins Medal Lecture from Harry Herr, MD] was a fascinating talk, and something that I think anyone could learn from,” says Kelly L. Stratton, MD, FACS.

“It was vitamin E and selenium in 2011-2012. There was a lot of hype about it. People were very excited. They lost their excitement in urology about it, but then along came vitamin D,” says Mark A. Moyad, MD, MPH.

“I think [it was a] great opportunity to catch up on what is going on with PSMA-PET and theranostics and then also understand that that landscape will change over the near future,” says Kelly L. Stratton, MD, FACS.

“It really was a multidisciplinary effort to pull the data together [and] provide the clinical implications [of] the genetic markers,” says Veda N. Giri, MD.

“It's very interesting to see how this continues to progress as a field,” says Kelly L. Stratton, MD FACS.

“Clinicians should do whatever they're able to try to limit or reduce the need for an intraoperative transfusion,” says Timothy D. Lyon, MD, FACS.

“The bulk of what we’re all grappling with are these new data for combining PARP inhibitors with androgen receptor–targeted agents in molecularly unselected populations,” says Tanya Dorff, MD.

“Major bladder reconstructive surgeries have the most room for improvement, particularly surgeries involving a bowel anastomosis,” says Sarah Hecht, MD.

“As people think about how we can do stone surgery more effectively, less morbidly for our patients, and less invasively, I think we're going to see robots enter our picture,” says Thomas Chi, MD.

“We need to be focusing our efforts on early exposure to the field for women and underrepresented groups,” says Bridget Lang Findlay, MD.

“It's important to put out information that's both accurate and helps to supplement in-office decision making in an outpatient setting,” says Daniel Bockelman.

Laura Bukavina, MD, MPH, discusses a highlight from the 2022 Society of Urologic Oncology Annual Meeting.

“We've got a lot of movement in terms of understanding how stones form, some pharmaceutical interventions that we can use to prevent stones, and then how we can get even less invasive to try to get stones in the least morbid way for our patients,” says Thomas Chi, MD.

“Perspectives on testosterone therapy and its use as it pertains to prostate cancer have certainly progressed over [the] years,” Diana Magee, MD, MPH, MSc.

Laura Bukavina, MD, MPH, summarizes a presentation from the 2022 Society of Urologic Oncology Annual Meeting from Sarah P. Psutka, MD, MS.

“It’s important for us to get the tools necessary to deal with patients who come with a unique set of difficulties,” says Laura Bukavina, MD, MPH.

“I just hope that people are as enthusiastic about this new company, as [I] and my coauthors are,” says Ruchika Talwar, MD.

"We're trying to figure out how to improve people's relationships with their genitals and like their sexual practices," says Christi Butler, MD.

"I think there's a lot of fear that can go into talking about these topics," says Katherine Rotker, MD.

“The combination of NAI plus BCG was safe, it was effective, and it serves as a feasible and viable alternative to other agents in this disease space,” says Karim Chamie, MD.

“I think my biggest piece of advice would be to get a social worker into your clinic because there's so many things that we can do,” says Mara Markzon, LCSW, ACM-SW.

“What we found is that the majority of these companies…offered our ‘secret shopper’ testosterone therapy,” says Joshua A. Halpern, MD, MS.

“First and foremost, it’s great that we have multiple lines of therapy for our bladder cancer patients,” says Tanya Dorff, MD.

Tanya Dorff, MD, explains how the next frontier in mCSPC will be the ability to select patients for treatment based more on molecular stratification and not only on disease volume or metachronous vs synchronous presentation.

“This study highlights how treatment remains influenced by where you live,” Diana Magee, MD, MPH, MSc.

“It's important to continue to speak up about what we have previously deemed controversial or taboo topics, such as family planning, pay disparities, and discrimination,” says Bridget Lang Findlay, MD.